ETFOptimize | High-performance ETF-based Investment Strategies

Quantitative strategies, Wall Street-caliber research, and insightful market analysis since 1998.


ETFOptimize | HOME
Close Window

David M. Magann, P.A. Reports on VA’s Innovative Approach to PTSD with Psychedelic Research

PTSD Treatment Veterans 1 scaled 1 panorama 9ddc91c584f1396077142070b4756316 opawun8c420h 1

Tampa, Florida – The Department of Veterans Affairs (VA) recently announced that it plans to fund research into the use of psychedelic substances to treat post-traumatic stress disorder (PTSD).

While several methods currently exist to treat PTSD, the use of psychedelic medications is new territory. One of the most commonly cited substances for further research is midomafetamine (MDMA), also known as “ecstasy” or “molly.” Early efforts to use MDMA in PTSD treatment have shown benefits for some veterans.

MDMA use is currently not legal in the United States. The US Food and Drug Administration (FDA) declined to approve MDMA for PTSD treatment in June 2024, saying that more testing is needed. Pharmaceutical company Lykos, which has been performing research on MDMA for PTSD, agreed that additional clinical trials are necessary.

Currently, only sertraline (Zoloft) and paroxetine (Paxil) have FDA approval for use in treating PTSD. Research supports the use of certain related medications, including fluoxetine (Prozac) and venlafaxine (Effexor). However, these medications are only “conditionally recommended” by the American Psychiatric Association (APA). The APA recommends non-medication therapies as a first line of treatment for PTSD.

Because military service includes the risk of exposure to potentially traumatic events, the rate of PTSD is slightly higher in veterans than in civilians. The VA estimates that about seven percent of veterans experience PTSD in their lifetimes, compared to 6 percent of the general population. The rate is higher for veterans who deployed or those who served in combat zones. Other factors, like military occupation, geographic location, and the type of enemy faced can also contribute to a higher PTSD risk.

PTSD is linked to several health conditions, including an early risk of mortality. For veterans living with PTSD, research into new therapies is important – and so is access to the benefits these veterans need today.

While the VA does provide benefits to veterans diagnosed with post-traumatic stress disorder, navigating the system to access those benefits can be challenging. Tampa attorney David W. Magann specializes in helping veterans access the disability benefits they need for PTSD, Gulf War Syndrome, and other conditions.



Attorney David Magann is a Marine Corps Veteran with a Criminology Degree from The University of South Florida and a Law Degree from The University of Miami. He will be your advocate working to get the benefits you have earned under the Department of Veterans Affairs. David Magann is also a social security and disability (SSI) lawyer. If you need a veteran's benefits lawyer or social security attorney, contact David W. Magann, PA at 1.855.418.9354.

David W. Magann, PA
156 West Robertson Street Brandon, FL 33511
1.855.418.9354
https://tampaveteranslawyer.com/
Press Contact : David Magann

Distributed by Law Firm Newswire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.


 

IntelligentValue Home
Close Window

DISCLAIMER

All content herein is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy, nor should it be interpreted as a recommendation to buy, hold or sell (short or otherwise) any security.  All opinions, analyses, and information included herein are based on sources believed to be reliable, but no representation or warranty of any kind, expressed or implied, is made including but not limited to any representation or warranty concerning accuracy, completeness, correctness, timeliness or appropriateness. We undertake no obligation to update such opinions, analysis or information. You should independently verify all information contained on this website. Some information is based on analysis of past performance or hypothetical performance results, which have inherent limitations. We make no representation that any particular equity or strategy will or is likely to achieve profits or losses similar to those shown. Shareholders, employees, writers, contractors, and affiliates associated with ETFOptimize.com may have ownership positions in the securities that are mentioned. If you are not sure if ETFs, algorithmic investing, or a particular investment is right for you, you are urged to consult with a Registered Investment Advisor (RIA). Neither this website nor anyone associated with producing its content are Registered Investment Advisors, and no attempt is made herein to substitute for personalized, professional investment advice. Neither ETFOptimize.com, Global Alpha Investments, Inc., nor its employees, service providers, associates, or affiliates are responsible for any investment losses you may incur as a result of using the information provided herein. Remember that past investment returns may not be indicative of future returns.

Copyright © 1998-2017 ETFOptimize.com, a publication of Optimized Investments, Inc. All rights reserved.